快訊／德國證實了！BNT執行長：提供臺灣疫苗「歐洲工廠生產」
復星醫藥11日晚間公告，公司控股子公司復星實業分別與臺積電、鴻海、永齡基金會以及裕利醫藥簽訂《銷售協議》，復星實業將向臺積電、鴻海、永齡基金會委託的裕利醫藥銷售共計1,000萬劑mRNA 新冠疫苗。
對此，BNT執行長兼聯合創始人吳沙忻（Ugur Sahin）表示，「自新冠疫情爆發以來，爲全球更多的人帶來安全有效的疫苗一直是BNT及合作伙伴們的共同目標。 很高興能爲臺灣民衆供應由我們歐洲工廠生產的新冠疫苗，與此同時，我們將持續評估該疫苗應對新增新冠病毒變異毒株的效果」。
原文：「We are glad to see that the vaccine co-developed by Fosun Pharma and BioNTech can play a positive role in the prevention and control of the epidemic in Taiwan. We will work closely with our partners to provide safe and effective vaccines to Taiwan at an early date, safeguarding the lives and health of Taiwan compatriots, and helping their life getting back on track as soon as possible；The doses are manufactured in Europe, and BioNTech will continue to evaluate the vaccine for use against additional variants of concern」。